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Case fatality rate for 
Ebola virus disease in 
west Africa
The case fatality rate (CFR) for the 2014 
Ebola outbreak in west Africa has been 
widely reported to be much lower than 
for most previous outbreaks.1 However, 
this low rate is not necessarily a feature 
of the infection itself. Rather, it is likely 
to be the result of a failure to account 
for delays between disease onset and 
ﬁ nal outcome. The low reported CFR 
values were generated from a so-called 
naive CFR calculation,2 in which the 
total number of deaths reported so 
far is divided by the total number 
of cases. Based on WHO reports 
up to Sept 7, 2014, which include 
2226 deaths and 4390 cases,1 the naive 
CFR estimate is 51% (95% CI 49–53%). 
This naive approach does not 
account for the delay between onset of 
Ebola symptoms and disease outcome 
(ie, recovery or death). During the 1976 
outbreak in Yambuku, Democratic 
Republic of the Congo,3 this delay 
was 7·5 days on average (appendix). 
In the middle of the outbreak, cases 
for which the outcome was as-yet 
unknown existed (appendix). 
Because the naive CFR calculation 
includes these cases—but not their 
outcomes—it generates a substantial 
underestimate of the actual CFR. 
Halfway through the 1976 outbreak, 
the naive CFR estimate would have 
been around 50%; as the outbreak 
reached its conclusion, this number 
would have climbed towards the much 
higher true value (ﬁ gure). By contrast, 
if we only consider cases with known 
outcomes, the realtime estimate of CFR 
remains consistently high throughout.
If cumulative incidences of cases 
and deaths are available, and delay 
from onset to outcome is known, 
the number of cases with outcomes 
can be estimated and hence a more 
accurate estimate of CFR obtained.4,5 
We estimate that the 2014 infection 
has an overall CFR of around 70% at 
present using the 1976 distribution 
of Ebola onset to outcome and WHO 
reports on total cases and deaths across 
all countries in 2014.1 If the delay is 
longer than in 1976, this CFR could be 
even higher.
The widely cited 2014 CFR of around 
50% is therefore likely to be a substantial 
underestimate of the true value, and so 
the number could apparently rise over 
the course of the outbreak. With data 
on individual onsets and outcomes, 
more precise estimates of CFR could be 
obtained, and how it varies with setting 
and availability of treatment could be 
assessed. 
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Figure: Realtime estimation of case fatality rate using data from the 1976 Yambuku Ebola outbreak
Data are from reference 3.
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Neuraminidase 
inhibitors for inﬂ uenza 
complications 
In their Comment (Aug 2, p 386),1 
Jonathan Nguyen-Van-Tam and 
colleagues suggest that ﬁ ndings from 
our Cochrane review2 and a study of 
observational data3 are consistent. 
In our review, which was based 
on full clinical study reports of all 
manufacturer-sponsored randomised 
trials, we did not find evidence that 
neuraminidase inhibitors improve 
important outcomes of influenza, 
whereas the Roche-funded individual 
analysis of a subset of retrospective case 
reports suggested that neuraminidase 
inhibitors do have some beneficial 
eﬀ ect. These observational studies were 
of patients admitted to hospital for 
influenza, some of whom apparently 
benefited from neuraminidase 
inhibitors.3 Most treated patients 
received oseltamivir, with a minority 
receiving zanamivir. Similar evidence 
was cited in a statement from Roche.4 
Our Cochrane review did not include 
similar patients, but was based on typical 
patients with inﬂ uenza-like illness.
However, the hypothesis that 
oseltamivir protects against compli-
cations of influenza proposed by 
